Effect of nebivolol on pulmonary artery remodeling in rats with high pulmonary blood flow

doi:10.3969/j.issn.2095-4344.2015.49.013

Abstract

Abstract:

BACKGROUND: It is still unclear whether nebivolol, a vasodilatory-type adrenergic β1 receptor antagonist, can effectively reduce pulmonary artery pressure and what is the effect on pulmonary vascular remodeling.
OBJECTIVE: To investigate the effect of nebivolol on pulmonary artery remodeling of rats with high pulmonary blood flow.
METHODS: Forty Sprague-Dawley rats were randomly divided into four groups: model, nebivolol, captopril and sham groups. Rats in the model, nebivolol and captopril groups were prepared to establish rat models of pulmonary hypertension and pulmonary vascular remodeling. Rats in the sham group were only subjected to separation of the abdominal aorta and inferior vena artery. After 5 days of modeling, the rats in the nebivolol group and captopril group were respectively intragastrically administered 1 mg/kg nebivolol solution and 5 mg/kg captopril solution daily. Rats in the model and sham groups were intragastrically administered the same amount of normal saline. After 8 weeks of administration, mean pulmonary arterial pressure, right ventricular hypertrophy index, pulmonary artery morphological changes, pulmonary artery ultrastructure and pulmonary arterial ring diastolic rate were compared among these four groups.
RESULTS AND CONCLUSION: Compared with the sham group, the muscularization of pulmonary arterioles of
rats in the model group was obvious; mean pulmonary artery pressure and right ventricular wet weight/(left ventricle wet weight+interventricular septum wet weight) were significantly increased (P < 0.05 or P < 0.01); pulmonary arterial ring diastolic rate was decreased (P < 0.05 or P < 0.01). Compared with the model group, mean pulmonary artery pressure and right ventricular wet weight/(left ventricle wet weight + interventricular septum wet weight) were significantly decreased (P < 0.05 or P < 0.01); the muscularization of pulmonary arterioles was alleviated and pulmonary arterial ring diastolic rate was increased in the nebivolol and captopril groups (P < 0.05 or P < 0.01). These results demonstrate that nebivolol can effectively alleviate pulmonary artery reconstruction in rats with high pulmonary blood flow through protecting vascular endothelium and reducing pulmonary artery pressure.

中国组织工程研究杂志出版内容重点：肾移植；肝移植；移植；心脏移植；组织移植；皮肤移植；皮瓣移植；血管移植；器官移植；组织工程

CLC Number:

R318

Chen Peng, Jiang Ping, Zhu Can-yang,Yang Mei, Ma Hong-jun, Li Yan-feng . Effect of nebivolol on pulmonary artery remodeling in rats with high pulmonary blood flow[J]. Chinese Journal of Tissue Engineering Research, doi: 10.3969/j.issn.2095-4344.2015.49.013.

Figures/Tables 6

References

[1] Neutel JM,Giles TD,Punzi H,et al.Long-term safety of nebivolol and valsartan combination therapy in patients with hypertension: an open-label, single-arm, multicenter study.J Am Soc Hypertens. 2014;8(12):915-920.

[2] Kamp O,Metra M,Bugatti S,et al.Nebivolol: haemodynamic effects and clinical significance of combined beta-blockade and nitric oxide release.Drugs. 2010;70(1):41-56.

[3] Ignarro LJ,Byrns RE,Trinh K,et al.Nebivolol: a selective beta(1)-adrenergic receptor antagonist that relaxes vascular smooth muscle by nitric oxide- and cyclic GMP-dependent mechanisms.Nitric Oxide.2002;7(2): 75-82.

[4] D'Agostino B,Gallellia L,Falciania M,et al.Nebivolol and airway responsiveness in the rabbit.Life Sci.2001; 68(18):2159-2168.

[5] Ocampo C,Ingram P,Ilbawi M,et al.Revisiting the surgical creation of volume load by aorto-caval shunt in rats.Mol Cell Biochem.2003;251(1-2):139-143.

[6] Pinar Yildiz.Molecular mechanisms of pulmonary hypertension. Clinica Chimica Acta 2009, 403: 9-16.

[7] KlingerJR.The nitric oxide/cGMP signaling pathway in pulmonary hypertension.Clin Chest Med. 2007;28(1): 143-167,ix.

[8] Mandegar M,Fung YC,Huang W,et al.Cellular and molecular mechanisms of pulmonary vascular remodeling:role in the development of pulmonary hypertension. Microvasc Res. 2004;68(2):75-103.

[9] Perros F,Ranchoux B,Izikki M,et al.Nebivolol for improving endothelial dysfunction, pulmonary vascular remodeling, and right heart function in pulmonary hypertension.J Am Coll Cardiol. 2015;65(7):668-680.

[10] Vermeersch P,Buys E,Pokreisz P,et al.Soluble guanylate cyclase-alpha1 deficiency selectively inhibits the pulmonary vasodilator response to nitric oxide and increases the pulmonary vascular remodeling response to chronic hypoxia. Circulation. 2007;116(8):936-943.

[11] Napoli C,Paolisso G,Casamassimi A,et al.Effects of nitric oxide on cell proliferation: novel insights. J Am Coll Cardiol. 2013;62(2):89-95.

[12] Sato J,Nair K,Hiddinga J,et al. eNOS gene transfer to vascular smooth muscle cells inhibits cell proliferation via upregulation of p27 and p21 and not apoptosis. Cardiovasc Res.2000;47(4):697-706.

[13] Bakris GL,Basile JN,Giles TD,et al.The role of nitric oxide in improving endothelial function and cardiovascular health: focus on nebivolol.Am J Med. 2010;123(7 Suppl 1):S2-8.

[14] Maffei A,Vecchione C,Aretini A,et al. Characterization of nitric oxide release by nebivolol and its metabolites.BAm J Hypertens.2006;19(6):579-586.

[15] Bayar E,Ilhan G,Furat C,et al.The effect of different β-blockers on vascular graft nitric oxide levels: comparison of nebivolol versus metoprolol.Eur J Vasc Endovasc Surg.2014;47(2): 204-218.

[16] Price A,Raheja P,Wang Z,et al.Differential effects of nebivolol versus metoprolol on functional sympatholysis in hypertensive humans.Hypertension.2013;61:1263-1269.

[17] Valentini M,Revera M,Bilo G,et al.Effects of beta-blockade on exercise performance at high altitude: a randomized, placebo-controlled trial comparing the efficacy of nebivolol versus carvedilol in healthy subjects.Cardiovasc Ther.2012; 30:240-248.

[18] de Nigris F,Rienzo M,Schiano C,et al. Prominent cardioprotective effects of third generation beta blocker nebivolol against anthracycline-induced cardiotoxicity using the model of isolated perfused rat heart.Eur J Cancer.2008; 44(3):334-340.

[19] Wolf SC,Sauter G,Jobst J,et al.Major differences in gene expression in human coronary smooth muscle cells after nebivolol or metoprolol treatment.Int J Cardiol. 2008;125(1): 4-10.

[20] Katragadda S,Arora RR.Role of angiotensin-converting engyme inhibitors in vascular modulation:beyond the hypertensive effects.Am J Ther.2010;17(1):11.

[21] Caglar N,Dincer I.Comparison between nebivolol and ramipril in patients with hypertension and left ventricular hypertrophy: a randomized open blinded end-point (PROBE) trial.Eur Rev Med Pharmacol Sci.2011;15:1359-1368.

[22] Frishman WH.b-Adrenergic blockade in cardiovascular disease.Cardiovasc Pharmacol Ther.2013;18:310-319.

[23] Fares H,Lavie CJ,Ventura HO. Vasodilating versus first -generation b-blockers for cardiovascular protection.Postgrad Med.2012;124:7-15.

[24] Waeber B,Feihl F.Nebivolol and valsartan: useful treatment for hypertension? Lancet.2014;383(6):1864-1866.

[25] Baker JG.The selectivity of β-adrenoceptor agonists at human β1-,β2- and β3-adrenoceptors. Br J Pharmacol. 2010;160: 1048-1061.

[26] Bundkirchen A,Brixius K,Bölck B,et al.Beta 1-adrenoceptor selectivity of nebivolol and bisoprolol. A comparison of [3H]CGP 12.177 and [125I]iodocyanopindolol binding studies.Eur J Pharmacol.2003;460(1):19-26.

[27] Rubin LJ. The Beta-Adrenergic Receptor in Pulmonary Arterial Hypertension:A Novel Therapeutic Target？J Am Coll Cardiol. 2015;65(7):681-683.

[28] Nodari S,Metra M,Dei Cas L.Beta-blocker treatment of patients with diastolic heart failure and arterial hypertension. A prospective, randomized, comparison of the long-term effects of atenolol vs. nebivolol.Eur J Heart Fail.2003;5:621-627.

[29] Conraads VM,Metra M,Kamp O,et al.Effects of the long-term administration of nebivolol on the clinical symptoms, exercise capacity,and left ventricular function of patients with diastolic dysfunction: results of the ELANDD study. Eur J Heart Fail. 2012;14:219-225.